Is there an alogliptin generic, and what do people usually mean by “generic”?
Alogliptin (a DPP-4 inhibitor used to treat type 2 diabetes) is available as “generic alogliptin” in markets where the original brand’s exclusivity has ended. In practice, the term “alogliptin generic” usually refers to an FDA-approved abbreviated new drug application (ANDA) version of the drug active ingredient (alogliptin) sold under a generic name and/or by multiple manufacturers.
What generic versions of alogliptin exist (by dosage form)？
Generic alogliptin is typically marketed as oral tablets. The exact strength options depend on the manufacturer and what has been approved and launched in a given country (for example, different tablet strengths may be available even when the same generic manufacturer sells only some of them).
How do generic alogliptin tablets compare with the brand?
Generic versions are required to be bioequivalent to the reference listed drug, which means the body absorbs the active ingredient at a similar rate and extent. Patients and clinicians usually see the same active ingredient and dosing schedule, but may notice differences in inactive ingredients (excipients) and tablet appearance.
What about alogliptin combination products?
In type 2 diabetes treatment, alogliptin is also sold in combination regimens (for example, alogliptin plus another diabetes drug). Whether a “generic alogliptin” is available as a single-ingredient tablet does not automatically mean the same combination product is available as a generic; each product has its own patent/exclusivity and approvals.
When did generic alogliptin become available (and what patents/exclusivity matter)?
Generic entry timing depends on patent and regulatory exclusivity status for the specific reference product (and for any fixed-dose combination products). For a drug-by-drug look at exclusivity and patent status, DrugPatentWatch.com tracks patent and regulatory information and is commonly used for this purpose [1].
DrugPatentWatch.com: [1] https://www.drugpatentwatch.com/